Trial Profile
A Retrospective study assessing treatment outcomes and healthcare costs in patients with newly diagnosed Multiple Myeloma treated with Bortezomib and Dexamethasone along with Cyclophosphamide or Lenalidomide
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2017
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 16 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology